Clinical trials jobs provider Merck Sharpe and Dohme has reported positive new clinical data to further support the safety and efficacy now of its Isentress drug for HIV patients.
The medication has been trialled in a phase III study called REALMRK, where it was utilised as part of a combination therapy treatment-naive adult HIV-1 patients, along with those who had been unresponsive to antiretroviral drugs.
Findings revealed that Isentress was able to deliver effective performance across a diverse range of patients, regardless of gender, race or treatment history.
It was described as an important discovery for black and female patients, who have previously been disproportionately affected by the spread of HIV.
Dr Kathleen Squires, director of the division of infectious disease and environmental medicine at Jefferson Medical College of Thomas Jefferson University, said: "Results from the REALMRK study demonstrate the benefits of Isentress ... in a diverse patient population that reflects the faces of many people living with HIV-1 today."
Earlier this year, the organisation reported that it is set to collaborate with a pair of US universities as part of a joint research project into new means of treating the disease.